Medtech Market Access in Europe: A Country-by-Country View
How Germany, France, UK, Italy, and Spain differ on HTA, reimbursement, and procurement — and how to sequence your European entry.
Germany
Largest market, NUB application pathway for hospital innovation, G-BA assessment for outpatient. Long but lucrative when economic story is tight.
France
HAS evaluation, LPPR listing, and CEPS pricing. Centralized and slow but predictable once inside.
United Kingdom
NICE MedTech evaluation, NHS Supply Chain procurement, and Integrated Care Systems for adoption. Evidence-heavy but commercially nimble post-Brexit.
Italy and Spain
Regional reimbursement, hospital tenders, and a strong KOL-driven adoption curve. Lower price points, higher volume potential.
Sequencing entry
Most companies should not enter all five at once. Pick one anchor country where you can hit positive HTA, then use that dossier to accelerate the next three.
Ready to put this into practice?
We embed with HealthTech, pharma, and medical device commercial teams as growth partners — not consultants. Start with a 10-minute Trust Audit or book a discovery call.